Alzheimer’s blood test gets FDA breakthrough device designation
Mar 14, 2024 — by Margarida Maia, PhD March 14, 2024. The U.S. Food and Drug Administration (FDA) has granted breakthrough device designation to Quanterix ’s experimental blood test measuring p-Tau 217, the protein that builds up as toxic tangles in the brains of people with Alzheimer’s disease. The test, Simoa p-Tau 217, has the potential to help doctors ...
CogniCann, Potential Alzheimer's Cannabinoid, Being Prepared for...
Apr 19, 2022 — by Lindsey Shapiro, PhD April 19, 2022. Sciensus Rare, a Dutch healthcare group, was given rights to distribute CogniCann, MGC Pharmaceutical’s cannabinoid-based investigative treatment for people with dementia and Alzheimer’s disease in Europe, should it be approved for commercial use or use in select early access programs. The agreement ...
Topline results of Phase 3 studies of simufilam for Alzheimer's...
Feb 8, 2024 — Two Phase 3 clinical trials are testing the effectiveness of simufilam, an experimental oral therapy that’s designed to improve cognition in people with Alzheimer’s disease.. Top-line results from the RETHINK-ALZ trial (NCT04994483) are expected by the end of this year, according to simufilam’s developer Cassava Sciences.Results from the second study, REFOCUS-ALZ study (NCT05026177), are ...
Alzheimer's therapy foralumab nasal spray cleared by FDA for...
Jul 11, 2024 — Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s disease, and the first patient is expected to be dosed soon. An expanded use program, also called a compassionate use program, gives a patient access ...
Simufilam found safe in review of ongoing Alzheimer’s clinical trials
by Andrea Lobo September 26, 2024. After completing a third review of interim safety data, an independent safety monitoring board has recommended the continuation — without modifications — of two ongoing Phase 3 clinical trials testing the oral therapy simufilam in people with Alzheimer’s disease. The board’s findings were announced by ...
Simufilam aids cognition in 47% of Alzheimer's patients in Phase 2...
Mar 14, 2023 — The Phase 2 trial runs for two years, with treatment safety and tolerability being measured over that time. Enrolled patients are randomized to a full two years of simufilam at 100 mg twice daily, or to one open-label year of treatment followed by six months of a placebo tablet (months 12 to 18), before returning to the treatment for a final six months.
Neurostimulation Device for Alzheimers Granted FDA …
Jan 25, 2021 — Non-invasive Neurostimulation Device Wins FDA’s Breakthrough Status. by Patricia Inacio, PhD January 25, 2021. Cognito Therapeutic ’s neurostimulation device — a next-generation digital therapeutic designed to treat memory and cognition symptoms in Alzheimer’s disease — has been granted a breakthrough device designation by the U.S ...
Signs of Alzheimer's reversed, eased after 3 months of TB006
Apr 21, 2023 — Nearly half of Alzheimer’s disease patients treated with TrueBinding ’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to data from an open-label extension (OLE) study. The findings expand on data from a completed Phase 2a trial (NCT05074498) that preceded the OLE ...
For Alzheimer's, Dementia Patients, a Water-filled Jelly Drop for...
May 24, 2022 — In the U.S., each tray starts at $9.99 while each Snackpot starts at $1.66 for subscribers. The price increases a few dollars if a customer does not choose the subscription service. Jelly Drops included in the trays have 12.5 milliliters of water, while the smaller Snackpots have 10 ml. The Alzheimer’s Society Accelerator Programme allowed ...
Alzheimer’s Disease Is Not a Mental Illness
May 17, 2021 — According to a 2013 article published in Administration and Policy in Mental Health, “Public stigma is a pervasive barrier that prevents many individuals in the U.S. from engaging in mental health care.”. The article notes that public stigma is “a set of negative attitudes and beliefs that motivate individuals to fear, reject, …